These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15507286)

  • 41. Rebuttal to: strong lupus anticoagulant can influence the prothrombin time INR falsifying the follow up of oral anticoagulation.
    Bailleul E; Van Vaerenbergh K; Lust A
    Thromb Haemost; 2005 Sep; 94(3):687; author reply 688. PubMed ID: 16268495
    [No Abstract]   [Full Text] [Related]  

  • 42. Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations.
    Favaloro EJ
    Semin Thromb Hemost; 2007 Apr; 33(3):290-7. PubMed ID: 17427064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura.
    Pierrot-Deseilligny Despujol C; Michel M; Khellaf M; Gouault M; Intrator L; Bierling P; Godeau B
    Br J Haematol; 2008 Aug; 142(4):638-43. PubMed ID: 18510681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved lupus anticoagulant assay.
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):122. PubMed ID: 1623114
    [No Abstract]   [Full Text] [Related]  

  • 45. Lupus anticoagulant and IgM anti-phospholipid antibodies in Korean children with Henoch-Schonlein purpura.
    Shin JI; Lee JS; Kim HS
    Scand J Rheumatol; 2009; 38(1):73-4; author reply 74-5. PubMed ID: 19191188
    [No Abstract]   [Full Text] [Related]  

  • 46. Lung adenocarcinoma and antiphospholipid antibodies.
    de Meis E; Monteiro RQ; Levy RA
    Autoimmun Rev; 2009 May; 8(6):529-32. PubMed ID: 19185619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-beta2-glycoprotein I antibodies--when and how should they be measured?
    Reber G; de Moerloose P
    Thromb Res; 2004; 114(5-6):527-31. PubMed ID: 15507287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis.
    Forastiero R; Martinuzzo M; Pombo G; Puente D; Rossi A; Celebrin L; Bonaccorso S; Aversa L
    J Thromb Haemost; 2005 Jun; 3(6):1231-8. PubMed ID: 15946213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
    Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
    Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lupus anticoagulant in patients infected by the HIV virus in its various stages].
    Elías Calvo CJ; Pérez Surribas D; Oteo Revuelta JA; Dorronsoro Ibero I
    Med Clin (Barc); 1993 May; 100(20):797-8. PubMed ID: 8321061
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
    de Laat B; Eckmann CM; van Schagen M; Meijer AB; Mertens K; van Mourik JA
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):757-64. PubMed ID: 19002041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic issues in thrombophilia: a laboratory scientist's view.
    Favaloro EJ
    Semin Thromb Hemost; 2005 Feb; 31(1):11-6. PubMed ID: 15706470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiphospholipid antibodies in young myocardial infarction patients.
    Mishra MN; Kalra R; Gupta MK
    Indian J Biochem Biophys; 2007 Dec; 44(6):481-4. PubMed ID: 18320848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Lupus anticoagulant].
    Gohchi K
    Nihon Rinsho; 1999 Sep; 57 Suppl():655-8. PubMed ID: 10543205
    [No Abstract]   [Full Text] [Related]  

  • 55. Quinidine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies.
    Clauser S; Fischer AM; Darnige L
    Am J Hematol; 2007 Apr; 82(4):330. PubMed ID: 16955465
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical laboratory testing for the antiphospholipid syndrome.
    Pierangeli SS; Harris EN
    Clin Chim Acta; 2005 Jul; 357(1):17-33. PubMed ID: 15893301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis.
    de Groot PG; Lutters B; Derksen RH; Lisman T; Meijers JC; Rosendaal FR
    J Thromb Haemost; 2005 Sep; 3(9):1993-7. PubMed ID: 16102105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IgM monoclonal gammopathy, lymphoid proliferations and lupus anticoagulant.
    Disdier P; Swiader L; Aillaud MF; Boucraut J; Harlé JR; Weiller PJ
    Am J Med; 1997 Mar; 102(3):319-20. PubMed ID: 9217609
    [No Abstract]   [Full Text] [Related]  

  • 59. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests.
    Galli M; Barbui T
    Semin Thromb Hemost; 2005 Feb; 31(1):17-24. PubMed ID: 15706471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine.
    Muscal E; Brey RL
    Int J Clin Pract; 2007 Sep; 61(9):1561-8. PubMed ID: 17596187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.